Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt [Yahoo! Finance]
Gyre Therapeutics, Inc. (GYRE)
Company Research
Source: Yahoo! Finance
Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock Every investor in Gyre Therapeutics, Inc. ( NASDAQ:GYRE ) should be aware of the most powerful shareholder groups. With 69% stake, public companies possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). As a result, public companies as a group endured the highest losses last week after market cap fell by US$51m. Let's take a closer look to see what the different types of shareholders can tell us about Gyre Therapeutics. What Does The Institutional Ownership Tell Us About Gyre Therapeutics? Institutional investors common
Show less
Read more
Impact Snapshot
Event Time:
GYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GYRE alerts
High impacting Gyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GYRE
News
- Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateGlobeNewswire
- Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisGlobeNewswire
- Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceGlobeNewswire
- Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
GYRE
Sec Filings
- 11/14/24 - Form S-3
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- GYRE's page on the SEC website